Crenolanib Besylate
The besylate salt form of crenolanib, an orally bioavailable benzimidazole targeting the platelet-derived growth factor receptor (PDGFR) subtypes alpha and beta and FMS-related tyrosine kinase 3 (Flt3), with potential antineoplastic activity. Upon oral administration, crenolanib binds to and inhibits both wild-type and mutated forms of PDGFR and Flt3, which may result in the inhibition of PDGFR- and Flt3-related signal transduction pathways. This results in inhibition of tumor angiogenesis and tumor cell proliferation in PDGFR and/or Flt3 overexpressing tumor cells. PDGFR and Flt3, class III receptor tyrosine kinases, are upregulated or mutated in many tumor cell types. [ ]
Term info
Crenolanib Besylate
- 4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-, Benzenesulfonate (1:1)
- CP-868,596-26
- CP-86859626
- CRENOLANIB BESYLATE
- Crenolanib Besylate
- [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine Monobenzenesulfonate
NCIT_C116978, NCIT_C63923, NCIT_C128784, NCIT_C157711, NCIT_C116977, NCIT_C157712
670220-93-6
CTRP, FDA
Crenolanib Besylate
MC4B01024K
http://purl.obolibrary.org/obo/NCIT_C17322
518325
518325
Crenolanib Besylate
Pharmacologic Substance, Organic Chemical
C3827141
C106204
Term relations
- Tyrosine Kinase Inhibitor
- Chemical_Or_Drug_Has_Mechanism_Of_Action some Receptor Tyrosine Kinase Inhibition
- Chemical_Or_Drug_Has_Physiologic_Effect some Inhibition of Cell Proliferation
- Chemical_Or_Drug_Has_Physiologic_Effect some Signal Transduction Inhibition
- Chemical_Or_Drug_Has_Physiologic_Effect some Positive Regulation of Apoptosis
- Chemical_Or_Drug_Affects_Gene_Product some Platelet-Derived Growth Factor Receptor